About Steen Bjerre

This author has not yet filled in any details.
So far Steen Bjerre has created 227 blog entries.

Potentially ideal profile for oral on-demand treatment of HAE

2019-05-07T12:49:00+02:00February 26, 2019|HAEi News|

In conjunction with the American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2019 in San Francisco, CA. KalVista Pharmaceuticals, Inc. CEO Andrew Crockett said: “We are pleased to provide additional data on KVD900, showcasing a potentially ideal profile for oral on-demand treatment of HAE. Both formulations tested were rapidly and highly absorbed, driving a [...]

Results Confirm Rapid Onset of Action, Sustained Activity and Robust Dose Response

2019-05-07T12:50:03+02:00February 24, 2019|HAEi News|

BioCryst Pharmaceuticals, Inc. reports additional topline data from the Phase 2 ZENITH-1 trial, including new data from the 250 mg and 500 mg dose cohorts. Data from the now complete trial confirm previously reported results showing a single dose of oral 750 mg BCX7353 was well-tolerated and superior to placebo (p<0.05) against the majority of [...]

Attune Advances Medication for Treatment of HAE

2019-02-20T11:20:23+02:00January 25, 2019|East & Southeast Asia, HAEi News|

Attune Pharmaceuticals, Inc. announces the completion of a $23 million Series B financing with the proceeds to be used to advance a pipeline including the ongoing clinical development of ATN-249, a novel orally-administered plasma kallikrein inhibitor for the treatment of HAE. Andrew McDonald, Ph.D., CEO of Attune, said, “This financing brings together a syndicate of [...]

Serving an important role in the management of HAE

2019-02-22T11:33:56+02:00January 23, 2019|HAEi News|

Following the presentation of two abstracts at the Western Society of Allergy, Asthma and Immunology (WSAAI) in Maui, Hawaii, USA, the Pharming Group N.V. COO Bruno Giannetti (MD, PhD) said: “This real-world evidence demonstrates that Ruconest continues to serve an important role in the management of HAE despite the availability of other therapeutic options.” The presentations are: [...]

Positive Phase 1 Results for Oral Plasma Kallikrein Inhibitor

2019-02-18T09:47:12+02:00January 22, 2019|HAEi News|

Attune Pharmaceuticals announces the positive results from the first in human studies evaluating ATN-249, a novel orally administered plasma kallikrein inhibitor for the treatment of HAE. The data were presented by Ira Kalfus, M.D., chief medical officer of Attune, as a poster presentation at the Western Society of Allergy, Asthma and Immunology (WSAAI) 2019 Annual [...]

Takeda Completes Acquisition of Shire

2019-02-18T09:47:20+02:00January 10, 2019|HAEi News|

Takeda Pharmaceutical Company Limited has completed its acquisition of Shire plc, becoming a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan. Takeda now has an attractive, expanded geographic footprint and leading position in Japan and the U.S., bringing its highly-innovative medicines to approximately 80 countries/regions with dedicated employees worldwide. Takeda’s R&D efforts are focused on [...]

KalVista Development Update and 2019 Clinical Plans

2019-02-18T09:47:24+02:00January 6, 2019|HAEi News|

“In December we filed with regulatory authorities to begin our Phase 2 study of KVD900 as a potential oral acute treatment for HAE. This enlarged study is expected to provide data in late 2019. We continue to be excited by the potential for KVD900 to provide a safe, oral on-demand option for HAE patients to [...]

“Global Perspectives” #4/2018 out now

2019-05-15T11:02:43+02:00December 21, 2018|HAEi News|

Dear HAE friends, With this fourth and final issue of the HAEi magazine Global Perspectives, we send you our sincerest best wishes for a festive holiday season and a healthy 2019. In this issue of our magazine you will, among many other items, find information on: HAEi South Eastern Europe Workshop 2018 HAEi Central Eastern Europe Conference and Workshop [...]

Enlarged Phase 2 Trial on Track

2019-02-18T09:47:31+02:00December 14, 2018|HAEi News|

KalVista Pharmaceuticals, Inc. has provided an operational update and released financial results for the fiscal second quarter ended October 31, 2018. CEO Andrew Crockett says: “We are still on track with our robust Phase 2 study for KVD900 as a potential acute therapy for patients with HAE. Our intention is to have an aggressive development plan [...]